Compare Globus Medical Inc. Class A Common Stock (GMED) vs Ulta Beauty Inc (ULTA) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

ULTA stock trades at $592.42, up 4.4% on the day, reflecting strong momentum after recent earnings beats and raised guidance. The technical outlook is bullish, with the current price near resistance at $589. Fundamentally, the company shows robust profitability with a 9.34% net margin and 46.12% ROE, though revenue growth has moderated. Analyst sentiment remains positive with a consensus price target of $624.93 and 60% buy ratings, supported by e-commerce strength and expansion into wellness categories.

The outlook for ULTA is favorable, driven by e-commerce acceleration and strategic initiatives, but risks include margin pressure from promotions and flat store traffic. Valuation at a P/E of 21.09 appears reasonable given growth prospects, yet execution on new categories and macroeconomic sensitivity to consumer spending are key watchpoints for sustained upside.